Endothelix Inc has developed a novel, non-invasive, inexpensive, and easy-to-use test-VENDYS® -for early detecting of cardiovascular disease that aids physicians identify patients at risk of heart attack and monitor their response to treatments. VENDYS® has been tested on more than 50,000 patients in numerous medical centers such as UCLA, Cedars Sinai, Johns Hopkins, and VIP clinics. The company has been funded $3.6M and obtained FDA approval.